Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Feb 26, 2026 (8 months ago)

Tirzepatide Inj

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Tirzepatide Inj, 15mg x 4, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-002-04.

Affected NDC 84223-0002-04

Compare with the code on your package — it is the most precise check available.

Drug: Tirzepatide

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Tirzepatide
NDC 84223-0002
1 mg/mg Powder Nomida LLC BULK INGREDIENT
Recalling firm
New Life Pharma LLC
NDC code
84223-002-04
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0395-2026 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Tirzepatide recalls

See all

Other recalls by New Life Pharma LLC

All 2026 recalls